TACROLIMUS EXTENDED RELEASE CAPSULES and PYREXIA

3,690 reports of this reaction

2.0% of all TACROLIMUS EXTENDED RELEASE CAPSULES reports

#9 most reported adverse reaction

Overview

PYREXIA is the #9 most commonly reported adverse reaction for TACROLIMUS EXTENDED RELEASE CAPSULES, manufactured by Astellas Pharma US, Inc.. There are 3,690 FDA adverse event reports linking TACROLIMUS EXTENDED RELEASE CAPSULES to PYREXIA. This represents approximately 2.0% of all 181,869 adverse event reports for this drug.

TACROLIMUS EXTENDED RELEASE CAPSULES has an overall safety score of 92 out of 100. Patients taking TACROLIMUS EXTENDED RELEASE CAPSULES who experience pyrexia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

PYREXIA3,690 of 181,869 reports

PYREXIA is a less commonly reported adverse event for TACROLIMUS EXTENDED RELEASE CAPSULES, but still significant enough to appear in the safety profile.

Other Side Effects of TACROLIMUS EXTENDED RELEASE CAPSULES

In addition to pyrexia, the following adverse reactions have been reported for TACROLIMUS EXTENDED RELEASE CAPSULES:

Other Drugs Associated with PYREXIA

The following drugs have also been linked to pyrexia in FDA adverse event reports:

ABACAVIR SULFATEACALABRUTINIBACETAMINOPHENACETAMINOPHEN 325MGACETAMINOPHEN 500MGACETAMINOPHEN, CAFFEINE, PYRILAMINE MALEATEACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, AND PHENYLEPHRINE HYDROCHLORIDEACETAMINOPHEN, DEXTROMETHORPHAN HBRACETAMINOPHEN, DEXTROMETHORPHAN HBR, DOXYLAMINE SUCCINATEACETAMINOPHEN, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCLACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDEACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, AND DOXYLAMINE SUCCINATEACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, AND PHENYLEPHRINE HYDROCHLORIDEACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, DOXYLAMINE SUCCINATEACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDEACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDEACETAMINOPHEN TABLET EXTENDED RELEASEACETYLCYSTEINEACYCLOVIRACYCLOVIR SODIUM

Frequently Asked Questions

Does TACROLIMUS EXTENDED RELEASE CAPSULES cause PYREXIA?

PYREXIA has been reported as an adverse event in 3,690 FDA reports for TACROLIMUS EXTENDED RELEASE CAPSULES. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is PYREXIA with TACROLIMUS EXTENDED RELEASE CAPSULES?

PYREXIA accounts for approximately 2.0% of all adverse event reports for TACROLIMUS EXTENDED RELEASE CAPSULES, making it a notable side effect.

What should I do if I experience PYREXIA while taking TACROLIMUS EXTENDED RELEASE CAPSULES?

If you experience pyrexia while taking TACROLIMUS EXTENDED RELEASE CAPSULES, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages

TACROLIMUS EXTENDED RELEASE CAPSULES Full ProfileAll Drugs Causing PYREXIAAstellas Pharma US, Inc. Drugs
Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.